ReviewTranslational lung cancer research2026
Utility of various programmed death-ligand 1 (PD-L1) assays in predicting the clinical benefit of immune checkpoint inhibitors in PD-L1-expressing non-small-cell lung cancer patients: a systematic review.
Review in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Peripheral T-Cell Receptor β Repertoire Dynamics Correlate with Response to Anti-PD-L1 Therapy in Non-Small Cell Lung Cancer.Cancers · 2026Article
- Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR-MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) targeting the programmed death ligand 1 (PD-L1)/programmed death-1 pathway are a mainstay for the treatment of patients with advanced/metastatic non-small cell lung cancer (NSCLC). Although some benefit has been observed in patients with low or no PD-L1 expression, ICIs are particularly recommended for those with PD-L1 expressing tumors. The limited availability of companion diagnostic (CDx) assays poses challenges for clinicians. Despite high analytical concordance among PD-L1 assays, the ability of alternative (non-comparison) assays to predict the clinical benefit of ICIs in the respective study populations has not been confirmed. This systematic literature review assessed whether alternative PD-L1 assays can predict the clinical benefit of ICI monotherapy for advanced/metastatic NSCLC with PD-L1 expression. Methods: Studies were sourced from PubMed and Google Scholar up to December 20, 2023. Included studies analyzed PD-L1 expression of patients with NSCLC treated with ICI monotherapy, reporting clinical outcomes [objective response rates (ORRs), progression-free survival (PFS), or overall survival (OS)]. Results: From 2,239 titles, four relevant trials (N=1,364) were included: two randomized controlled trials of atezolizumab, and two retrospective studies of nivolumab. These trials indicated that the PD-L1 22C3 pharmDx and Ventana PD-L1 SP263 assays may predict the benefit of atezolizumab in patients with NSCLC. Conclusions: These results may expand the therapeutic options for patients with PD-L1-expressing advanced/metastatic NSCLC using alternative PD-L1 assays. This review was limited by different patient populations, small numbers, possible inter-pathological discordance, and study heterogeneity. Evidence for nivolumab, pembrolizumab, or durvalumab remains inconclusive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.